文献速递乳腺乳腺X线MR

DENSE-2试验:对比增强乳腺摄影或简化MRI用于极度致密乳腺 supplemental筛查

Supplemental Breast Cancer Screening with Contrast-enhanced Mammography or Abbreviated MRI for Extremely Dense Breasts: The DENSE-2 Trial.
PubMed 文献 · Radiology · 2026-01-01

DENSE-2是一项嵌入荷兰筛查项目的多中心随机对照试验,针对乳腺极度致密且筛查乳腺X线阴性的女性,比较补充筛查采用对比增强乳腺摄影(CEM)或简化MRI(AB-MRI)能否较乳腺X线降低间期癌。试验包含连续两轮筛查,每人两轮使用同一技术,旨在评估两种方法的性能、可行性与可接受性,并支持筛查策略决策。

要点

  • 对象为极度致密乳腺且筛查X线阴性者,补充筛查用CEM或AB-MRI。
  • 主要目的是比较两种方法能否降低间期癌,参照为乳腺X线筛查。
  • 两轮筛查用同一技术,关注性能、可行性与可接受性。

核心结论

  • DENSE-2旨在确定CEM或AB-MRI补充筛查是否较乳腺X线降低极度致密乳腺女性的间期癌。
  • 试验将提供两种筛查方式的性能、可行性与可接受性信息,并支持筛查策略建模与决策。

研究设计与样本

  • 多中心随机对照试验,嵌入荷兰人群乳腺筛查项目,注册号NCT06636370。
  • 对象为乳腺极度致密且筛查乳腺X线阴性的女性,包含连续两轮筛查。
  • 每名女性两轮均接受同一乳腺影像技术,比较CEM或AB-MRI补充筛查与乳腺X线。

临床应用与阅片要点

  • 对极度致密乳腺且X线筛查阴性者,可关注CEM或AB-MRI作为补充筛查的随机试验证据。
  • 两轮使用同一技术设计有助于观察重复筛查下的性能与可接受性。

局限性

  • 原文为试验方案介绍,尚未报告CEM或AB-MRI的性能数值与间期癌结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Women with extremely dense breasts have an increased risk of breast cancer but also a decreased sensitivity of mammography. The Dense Tissue and Early Breast Neoplasm Screening (DENSE) trial, initiated in 2011, showed that supplemental full-protocol MRI screening reduced the number of interval cancers in women with extremely dense breasts. Cost-effective screening scenarios have been described, but imaging costs and capacity remain barriers to implementing full-protocol MRI in population-based breast cancer screening programs. Therefore, the DENSE-2 trial was set up to investigate two alternate screening techniques, contrast-enhanced mammography (CEM) or abbreviated MRI (AB-MRI), that are expected to be cheaper and to make more efficient use of the available capacity while potentially achieving similar results to full-protocol MRI. DENSE-2 is a multicenter randomized controlled trial embedded in the Dutch screening program. It comprises two consecutive screening rounds in which women receive the same breast imaging technique both times. The trial investigates the value of supplemental screening with CEM or AB-MRI in women with extremely dense breasts with a negative screening mammogram. The primary aim is to determine whether these methods will lead to a reduction of interval cancers compared with mammography. The DENSE-2 trial results will provide insights into the performance, feasibility, and acceptability of both screening modalities, enable long-term outcome modeling, and support decision-making on the most appropriate screening strategy for women with extremely dense breasts. ClinicalTrials.gov: NCT06636370 © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Bahl in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. van Grinsven SEL, Monninkhof EM, Mann RM, et al. Supplemental Breast Cancer Screening with Contrast-enhanced Mammography or Abbreviated MRI for Extremely Dense Breasts: The DENSE-2 Trial. Radiology. 2026. PMID: 42867374. doi:10.1148/radiol.260333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。